Company Profile

X-In8 Biologicals Corporation
Profile last edited on: 1/15/14      CAGE: 5LM96      UEI: F135FGK8SD46

Business Identifier: therapies to fight inflammation and other tissue damage
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

741 Pinehurst Drive
Chapel Hill, NC 27517
   (919) 967-2859
Location: Single
Congr. District: 04
County: Orange

Public Profile

Biotechnology company X-in8 Biologicals Corp., a spinoff from the laboratories at the University of North Carolina at Chapel Hill. X-in8 is developing therapies that can fight inflammation and other tissue damage as blood flow is restored after the blood supply has been restricted for a period of time, such as after an organ transplant. The damage that can occur is called ischemia-reperfusion injury, or IRI. Prncipals of the firm are working on a way to keep naturally occurring proteins from contributing to IRI. Egan said the compounds he is developing could reduce tissue damage after transplants. The technology could also be developed for heart surgery as well as heart attack and stroke applications.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2011 1 NIH $291,826
Project Title: Tlr4 Inhibition To Reduce Cerebral Ischemia Reperfusion Injury
2010 1 NIH $321,746
Project Title: The Effect of Tlr4 Inhibition on Lung Transplant Ischemia-Reperfusion Injury

Key People / Management

  Thomas Egan -- President

  Perry A Genova -- President & CEO

  Lori Ann Holle

Company News

There are no news available.